Currently, ongoing Phase 1 and 2 clinical trials are investigating the efficacy of RIG-I agonists in several tumor types, including gliomas, indicating the potential versatility of these therapeutic agents in inducing cell death and modulating cytokines (63, 64). The gene discussed is RIGI; the disease is neoplasm.